Prognostic or predictive value of mgmt promoter methylation in gliomas depends on IDH1 mutation

Neurology

Volumn 82, Issue 23, 2014, Pages 2147-2148

  Chamberlain, Marc C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; TUMOR MARKER;

ASTROCYTOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHROMATIN; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; EDITORIAL; GENE INTERACTION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; ISOCIDUE DEHYDROGENASE 1 GENE; METHYLATION; METHYLGUANINE METHYLTRANSFERASE GENE; OLIGODENDROGLIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GENE; WILD TYPE;

CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; TUMOR SUPPRESSOR PROTEINS;

EID: 84903977931     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000451452.30826.6b     Document Type: Editorial

References (7)

1. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81: 1515-1522.
2. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27: 5874-5880.
3. van den Bent MJ, Brandes AA, Taphoorn M, et al. Adjuvant provarbazine, lomustine and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-Term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 2013;31: 344-350.
4. Wick W, Platten M, Meisner C, et al; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13: 707-715.
5. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3: 709-722.
6. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013;126: 443-451.
7. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013; 126: 907-915.